Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Rainwater Charitable Foundation Announces Fourth-Annual Rainwater Prize Winners for Brain Research

This image opens in the lightbox

News provided by

The Rainwater Charitable Foundation

26 Jan, 2023, 14:00 GMT

Share this article

Share toX

Share this article

Share toX

Honorees are recognized for their innovative scientific discoveries for neurodegenerative diseases

FORT WORTH, Texas, Jan. 26, 2023 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative disease research, today announced this year's recipients of the Rainwater Annual Prize for Outstanding Innovation in Neurodegenerative Disease Research and for Innovative Early Career Scientist. This year's Outstanding Innovation Prize will be awarded to a team: Dr. C. Frank Bennett, Ionis; Dr. Don W. Cleveland, University of California San Diego (UCSD); and Dr. Timothy M. Miller, Washington University. Dr. Susanne Wegmann, German Center for Neurodegenerative Diseases (DZNE) will be awarded the Rainwater Prize for Innovative Early-Career Scientist. The prizes will be presented during the Eurotau 2023 Conference on April 27, 2023 in Lille, France.

The Rainwater Prize Program recognizes scientific progress toward new treatments for neurodegenerative diseases associated with the accumulation of tau protein in the brain and fosters scientific discovery by elevating awareness of the gaps in neurodegenerative research, bringing new researchers into the tauopathy field, and awarding scientific achievements that could lead to innovative, effective treatments.

Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research will be shared by:

Collaborators Drs. Bennett, Cleveland and Miller for their work advancing antisense technology for the treatment of neurodegenerative diseases including ALS, Huntington's disease, Alzheimer's disease and tauopathies over the past 20 years.

  • Dr. Bennett, Chief Scientific Officer at Ionis, continues to advance antisense technology and expand Ionis's drug discovery platform. He has been working on antisense oligonucleotides for the past 30 years. He started investigating the potential of antisense technology for developing therapies for ALS and spinal muscular atrophy (SMA) almost 20 years ago. The first drug for the treatment of SMA, nusinersen, was approved by the FDA in 2016 and subsequently has been approved in more than 50 countries world-wide. He is currently working on a treatment for Huntington's disease, which is in late-stage clinical trials and is leading the discovery and development of other drugs for neurological diseases.
  • Dr. Cleveland, Chair and Distinguished Professor of Cellular and Molecular Medicine at UC San Diego, discovered, purified, and determined the properties of the tau protein, the major component of the intracellular filamentous deposits that define a number of neurodegenerative diseases including Progressive Supranuclear Palsy. With Bennett and Miller, he developed designer DNA drugs that utilize technology that silence genes in the human nervous system that have been studied in seven different clinical trials, aiming to treat ALS, Huntington's Disease, Parkinson's Disease, and Alzheimer's Disease.
  • Dr. Miller, Vice Chair of Research and David Clayson Professor of Neurology at Washington University School of Medicine in St. Louis, has been a leader for over two decades in helping uncover effective therapies for neurodegenerative diseases including ALS and tauopathies. In 2007, Dr. Miller created an ALS translational research program and launched promising trials to improve the lives of people with neurological disorders. The latest results using the SOD1 ASO developed with Cleveland and Bennett show a dramatic effect on slowing of SOD1 ALS. His lab led the early stages of development of BIIB080/IONIS-MAPTRx, an antisense drug that lowers tau mRNA and protein as a therapy for tauopathies.

"This prize is an honor and I look forward to using this research funding to further the next generation of efforts," said Dr. Cleveland. "The Rainwater Prize money will help continue the development of strategies to grow new neurons and suppress Tau chronically."

Rainwater Prize for Innovative Early-Career Scientist:

  • Dr. Wegmann, Research Group Leader at DZNE, is studying tau protein actions in neurodegenerative diseases by utilizing different experimental models and methodologies to discover tau's normal function and misfunction in the diseased brain. She finds a way to master the difficult translational leap, from test tube to human, by validating biochemical, biophysical and cytological results on postmortem human brain tissue. Her general interest in solving difficult problems drove her to get an engineering degree and later expand into biophysics and brain pathology of tau. Currently, Wegmann and her group focus on identifying new interactions of Tau and determining the role of tau phase separation in Alzheimer's disease and tauopathies.

"I feel very honored! With the prize money, I will further push my research into how the tau protein exerts its toxic effect in different ways, which are not fully understood," said Dr. Wegmann. "We do not understand the actual function of this protein yet and will try to expand our knowledge of its basic biology to aid in disease research."

Drs. Cleveland, Bennett, Miller, and Wegmann were nominated for the Rainwater Prize's Outstanding Innovation ($400,000) and Early-Career ($200,000) Prizes based on published and peer-reviewed research that contributed significantly to neurodegenerative disease research. They were selected based on the quality of research and applicability to a tauopathy, leadership, mentorship, and positive impact within the scientific community.

"I could not be more excited about this year's winners of the Rainwater Prize," said Todd Rainwater, Trustee of the Rainwater Charitable Foundation. "The presentation of the Outstanding Innovation Prize to a collaborative group of scientists advancing drug discovery efforts recognizes the importance of team science. The selection of Dr. Wegmann for this year's early-career prize highlights the exciting scientific discoveries happening in Europe and across the globe. I know my dad would be so proud of these scientists and their important advances to the field."

For more information on this year's prize winners, please visit www.rainwaterprize.org.

About the Rainwater Charitable Foundation's Medical Research
The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist Richard E. Rainwater. RCF supports a range of programs in K-12 education, medical research, and other worthy causes. In order to deliver on its mission to accelerate the development of new diagnostics and treatments for tau-related neurodegenerative disorders, the Rainwater Charitable Foundation Medical Research Team manages the Tau Consortium and the Rainwater Prize Program. With over $161 million invested in medical research to date, the Rainwater Foundation has helped to advance eight treatments into human trials. For more information, please visit rainwatercharitablefoundation.org. 

Corporate Contact: 
Jordan Brainerd 
Rainwater Charitable Foundation
jbrainerd@rainwatercf.org
(817) 820-2708 

Media Contact: 
Shannon Fox
Edelman
shannon.fox@edelman.com 
(646) 262-7427

Logo - https://mma.prnewswire.com/media/1989850/RCF_Logo.jpg 

Modal title

Also from this source

The Rainwater Charitable Foundation Unveils 2025 Rainwater Prize Winners, Honoring Researchers' Dedication to Primary Tauopathies and Neurodegenerative Diseases

The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative research that enables field-advancing programs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Banking & Financial Services

Banking & Financial Services

Awards

Awards

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.